Figure 1A

Synergistic effect of Compound 41-A and sorafenib

on tumor burden (tumor free mice)

Treatment	**Examination of the liver for superficial tumor nodules**
Vehicle	0/10 tumor nodule free
Compound 41-A	0/10 tumor nodule free
Sorafenib	0/10 tumor nodule free
Compound 41-A + Sorafenib	**2/10** tumor nodule free

Figure 1B




Figure 2



A
CD45+ total immune cell infiltarte
% of Total
50
40
30
20
10
0
Vehicle
41-A
Sorafenib
41-A+Sorafenib
B
PD-L1 on CD45-
% of CD45-
80
60
40
20
0
**
*
*
Vehicle
TLR7-ASIP
Sorafenib
TLR7+Sorafenib
C
CD11b- lymphoid cells
% of CD45+
80
60
40
20
0
***
**
***
**
Vehicle
41-A
Sorafenib
41-A+Sorafenib
D
CD11b+ myeloid cells
% of CD45+
80
60
40
20
0
**
*
**
*
Vehicle
41-A
Sorafenib
41-A+Sorafenib

Figure 3




Figure 4




Figure 5A



treatment start
100
50
0
% survival
0
20
40
60
80
100
days after inoculation
vehicle
41-A (10mg/kg)
αPD-1
41-A + αPD-1

Figure 5B

Treatment	Examination of the liver
Vehicle	0/7 tumor free
αPD-1	1/9 tumor free
42-A	1/7 tumor free
42-A+αPD-1	3/9 tumor free




Figure 6A



72 hours
120 hours
148 hours
Cell count
relative to DMSO CTRL [%]
250
200
150
100
50
0
EGI 1
Hep3B
HepG2
HLE
HLF
Huh7
JHH1
JHH2
JHH4
JHH5
JHH6
OZ
SkHep1
SNU449
270pM
27µM

Figure 6B



EGI1
Hep3B
HepG2
HLF
Huh7
JHH2
SkHep1
Cellcount [%]
normed to untreated
41c-A [µM]
0
50
100
150
200
250
0.0001
0.001
0.01
0.1
1
10
100

Figure 7A



donor #1
donor #2
donor #3
JHH2
HepG2
HLF
JHH1
SNU449
OZ
Hep3B
Huh7
Cell count
relative to media CTRL [%]
0
50
100
150
200
media CTRL
whole blood w/o
whole blood + 41c-B

Figure 7B



JHH5
JHH6
HLE
EGI1
JHH4
SkHep1
Cell count
relative to media CTRL [%]
200
150
100
50
0
media CTRL
whole blood w/o
whole blood + 41c-B
donor #1
donor #2
donor #3

Figure 7C



EGI1
Hep3B
HepG2
HLF
Huh7
JHH2
SkHep1
Cellcount related to untreated [%]
200
150
100
50
0
media CTRL
whole blood w/o
whole blood + 41c-A
Donor #4
Donor #5

Figure 8




Figure 9




Figure 10

